Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Vir Biotechnology, Inc.’s VIR share price has dipped by 5.45%, which has investors questioning if this is right time to buy.

Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 ...

The Biotechnology Master of Science degree program provides students with advanced coursework in biotechnical and biomolecular sciences. Graduates are prepared for positions in research, and ...

Dr Rajesh Gupta, vice president, global health portfolio and public-private partnerships at Vir Biotechnology, said: “COVID-19 reinforced the ever-present global threat of infectious diseases ...

Remnants of the old grey logo with its central O cut out and with muted metallic tones still appear in various banners and sections of the website as of now. Many players on Reddit are missing the ...

The BioXplorer 400 has been fitted with four bioreactors along with working volumes of up to 400 mL. It is an ideal tool for parallel bioprocess optimization. The highly configurable nature of ...

5 analysts have expressed a variety of opinions on Vir Biotechnology (NASDAQ:VIR) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...